Clinical Trials Browser

Phase 2 × ribociclib × 30 days × Clear all

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

57 enrolled

Breast

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

200 enrolled

Breast

Locoregional Recurrence

NCT07405801 2026-04-06

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT05843253 2026-03-20

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

120 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Clinical Trials

Ribociclib (LEE011) Rollover Study for Continued Access

FAIM

RaPhLRR

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant